Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze) (2020) Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. Conference contribution MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2020) Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, et al. Journal article Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium (2020) Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, et al. Journal article A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2019) Eigentler T, Krauss J, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial (2019) Kreutzfeldt S, Apostolidis L, Oles M, Horak P, Heilig CE, Heining C, Hutter B, et al. Conference contribution Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (2019) Tesch H, Loibl S, Kast K, Jackisch C, Moebus V, Buchen S, Untch M, et al. Conference contribution Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC) (2019) Furlanetto J, Nekljudova V, Schneeweiss A, Thode C, Denkert C, Untch M, Bassy M, et al. Conference contribution Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Conference contribution Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al. Conference contribution Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto (2019) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Journal article